Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report) and Ocular Therapeutix (OCUL – Research Report).
Alkermes (ALKS)
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on Alkermes, with a price target of $35.00. The company’s shares closed last Thursday at $23.76, close to its 52-week low of $22.01.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alkermes with a $35.50 average price target, representing a 48.8% upside. In a report issued on April 9, Stifel Nicolaus also maintained a Hold rating on the stock.
See the top stocks recommended by analysts >>
Ocular Therapeutix (OCUL)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix today and set a price target of $16.00. The company’s shares closed last Thursday at $5.86.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocular Therapeutix with a $16.50 average price target, representing an 117.1% upside. In a report issued on April 8, Piper Sandler also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALKS:
- Alkermes price target lowered to $23 from $25 at UBS
- Biotech Alert: Searches spiking for these stocks today
- Alkermes narcolepsy drug ‘could be best-in-class,’ says Mizuho
- Alkermes price target raised to $50 at Jefferies after ‘excellent’ NT2 data
- Alkermes narcolepsy data better than expected, says Stifel
